Back to photostream

Amicus to delay filing for U.S. marketing rights for lead drug

(Reuters) - Amicus Therapeutics Inc said it was unlikely to submit a U.S. marketing application for its lead drug, to treat Fabry disease, by the end of 2015 as expected, after U.S. health regulators asked for a more comprehensive analysis of trial data.

feeds.reuters.com/~r/reuters/healthNews/~3/iNYquCV3MRU/st...

26 views
0 faves
0 comments
Uploaded on October 2, 2015